Novo Nordisk said a higher dose of its drug Wegovy led to greater weight loss in patients during a late-stage trial, but the ...

People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

Body Mass Index (BMI) has limitations as it doesn't distinguish between muscle and fat, leading to misclassification of ...

Despite the staggering impact of obesity on the Black community, columnist Justice B. Hill argues that the issue has been ...

A new report says only using BMI to determine if a patient has obesity leads to under-diagnosing people who are ill and ...

A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less ...

Novo Nordisk said patients taking a bigger dose of its blockbuster obesity drug lost more weight than those on a lower dose, ...

The way clinicians diagnose obesity is set to change with new guidelines acknowledging that not all obese have the same ...

The longtime reliance on BMI means that obesity is likely overdiagnosed, members of the Commission said. View on euronews ...

New Activin R-based medications can emerge as perfect solutions for balancing weight loss and muscle building, making a ...

Research shows that people with a certain body shape face a higher risk of serious health problems compared to their ...

Novo Nordisk (NVO) stock slipped after ate-stage trial data for a higher-dose version of its popular obesity therapy, ...